Inve India ▾

Ind-Swift Laboratories share price & results

Ind-Swift Laboratories Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Chandigarh-based finished-dosage formulation maker exporting branded generics and CMO products to 85+ countries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue191 ₹ crore+24.8% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin17.0 %+14.6 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit25.0 ₹ crore+177.8% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity5.08 %+2.2 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin-23.88 %−14.5 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)53.94 %+68.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

11 targets tracked, none judged yet · 11 open · verdicts reflect calls analysed to Q1 FY27.

Ind-Swift Laboratories Limited management guidance track record on Inve: 11 targets tracked across analysed earnings calls (0 achieved, 0 missed, 11 open).

TargetOriginal wordingSaidLatest callVerdict
Incremental revenue from CDMO partnerships₹200 to ₹220 crore
Call transcript, Q1 FY27 · 17 Aug 2026		Q1 FY27Q1 FY27:Expected to contribute an incremental revenue of ₹200 to ₹220 crore in FY27 from Viatris, Manx, and Arrotex partnerships.
Call transcript, Q1 FY27 · 17 Aug 2026		New

Source: Inve Guidance Tracker for Ind-Swift Laboratories Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

11 of Ind-Swift Laboratories Limited's 11 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 10 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹368.8 +9.42% · +₹31.75

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +261.8% 1Y

₹100₹200₹300₹400Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q1 FY27 — 17 Aug 2026

1Y: ₹101.94 on 24 Oct 2025 → ₹368.8. High ₹413.1 (29 Sept 2026), low ₹88.15 (31 Dec 2025).

Previous close
₹337.05
Market cap
₹2.9k Cr
52-week range
₹88.15 – ₹413.1
One year
+255.47%
Price to earnings (TTM to Jun 2026)
45.09×
Return on equity (TTM to Jun 2026)
5.08%

Overview

Symbol
NSE:INDSWFTLAB
Exchange
NSE
Currency
INR

What Ind-Swift Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Ind-Swift Laboratories is a Chandigarh-headquartered finished-dosage formulation manufacturer that divested its API & CRAMS business and merged with group company Ind-Swift Limited to become a pure-play formulations company. It manufactures tablets, capsules, injectables, liquids, dry syrups and sachets across plants at Derabassi, Parwanoo and Jammu, including a 100% export-oriented Global Business Unit (GBU) at Derabassi accredited by UK-MHRA, TGA, Health Canada and WHO-GMP. The company earns through contract manufacturing (CMO) for global generics majors, direct commercial export supply and out-licensing of its own dossiers in regulated markets, alongside a domestic business selling branded Ethical and trade-generic formulations through its own field force and stockist network.

Segments

  • International Division (Global Business Unit / Export)
  • Ethical Division (Domestic)
  • Generics Division (Domestic)
  • P2P Division (Contract Manufacturing, Domestic)
  • Others (Q-DEN / NOVA)
Manufacturing facilities
3 formulation plants (Derabassi, Parwanoo, Jammu) plus a dedicated R&D centre in Panchkula; a greenfield facility is under development in Mohali, Punjab
Installed annual capacity
9,600 million tablets, 186 million capsules and 118 million sachets per annum
Countries with market presence
85+
Product registrations filed globally
750+
Global regulatory approvals received
520+
Dossiers filed globally
1,915+
Founded 1995Headquarters Chandigarh, India Company website

How the price took the results

close before → close after

Q1 FY27
+2.9%
17 Aug

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Ind-Swift Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Ind-Swift Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Ind-Swift Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.